Deadline for Registration: August 1, 2021
Abstract:
Cardiovascular diseases are major causes of mortality worldwide. A fixed-dose combination therapy—the so-called polypill—was proposed more than 15 years ago as an acceptable and cost-saving approach to reduce cardiovascular disease risk. Since then, different formulations of polypill have been used in several studies worldwide.
The research work of Prof. Reza (PolyIran Study) proposes a fixed-dose combination therapy (polypill strategy) as an approach to reduce the burden of cardiovascular disease, especially in low-income and middle-income countries (LMICs). The PolyIran study aimed to assess the effectiveness and safety of a four-component polypill including aspirin, atorvastatin, hydrochlorothiazide, and either enalapril or valsartan for primary and secondary prevention of cardiovascular disease. This study is the first large-scale, long-term, pragmatic randomized trial to investigate the effects of a fixed-dose combination therapy on primary or secondary prevention of cardiovascular disease
Target Audience:
The webinar is open to researchers, academicians, scientists and healthcare professionals from the OIC member states.
For Registration please visit: Click here
Procedure to Join: Zoom link will be shared with selected participants
Profile of Speaker:
Prof. Malekzadeh is a Distinguished Professor in Internal Medicine and Director, Digestive Disease Research Institute in Tehran University of Medical Sciences. He obtained his MD, specialty board of medicine and subspecialty board of gastroenterology from Shiraz University of Medical Sciences, Iran. He has worked in various capacities in Iranian medical education and research system. In Addition, he was chancellor of Shiraz University; Minister of Health and Medical Education (MOHME) and secretary of Iranian Academy of Medical Sciences.
Moreover, he is a member of 18 national and international academies and scientific societies. He has published 729+ papers in scientific international journals with 99191+ citations and is among the top 1% world highly cited scientists in clinical Medicine based on Essential Science Indicators. His h-index is 104 in Scopus. Prof. Reza has also established the Golestan Cohort and Persian cohort study in Iran.
Furthermore, Prof. Malekzadeh has received 14 national awards including Razi, Avicenna, Yalda, Hadavi, Tabatabaei and Iranian Science awards. He has been awarded the Medal of Honor from International Agency for Research on cancer (IARC/WHO) for outstanding contribution in research on cancer (2018).
Webinar Coordinator:
Muhammad Haseeb Ahmad
Program Officer
COMSTECH, Islamabad.
Email: Haseeb.ahmad@comstech.org
Phone: +92 51 9220681
